Barath Jagadisan

Barath Jagadisan

Auto-generated profile, based on publicly available information

Barath Jagadisan

Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in Current Hepatology Reports
Verified
Journal Article
Open access
PDF file
BJBarath Jagadisan
Barath Jagadisan
ADAnil Dhawan
Anil Dhawan
Purpose of Review: Recombinant adeno-associated virus (rAAV) is the commonest viral vector used in gene therapies. With the increase in the number of such therapies being employed in human clinical trials and approved clinical use, the associated adverse events are increasingly observed. Hepatotoxicity is the most common adverse event. Recent Findings: Although mild in most, hepatotoxicity may affect gene therapy efficacy, lead to acute liver failure, death and persisting hepatitis necessitating prolonged use of immunosuppressants. There has been an increase in the referrals of such cases to hepatologists. Summary: There is a lack of good quality evidence on the use of reactive immunosuppressants. There is a need to devise empiric protocols to diagnose and treat hepatotoxicity based on the side-effect profile of individual gene therapy, the present understanding of immunological basis of hepatotoxicity, the experience with various immunosuppressants in other disorders and the unique challenges and requirements of gene therapy.

3 January 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
BJBarath Jagadisan
Barath Jagadisan
ADAnil Dhawan
Anil Dhawan

22 February 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
BJBarath Jagadisan
Barath Jagadisan
AVAnita Verma
Anita Verma
MDMaesha Deheragoda
Maesha Deheragoda
ADAkash Deep
Akash Deep
TGTassos Grammatikopoulos
Tassos Grammatikopoulos
ADAnil Dhawan
Anil Dhawan

24 November 2020 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
SVSrinivas Srinidhi Vadlapudi
Srinivas Srinidhi Vadlapudi
BJBarath Jagadisan
Barath Jagadisan
RARamesh Ananthkrishnan
Ramesh Ananthkrishnan
SNSunil Narayanaswamy
Sunil Narayanaswamy

1 November 2018 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
SPShikhar Pradhan
Shikhar Pradhan
BJBarath Jagadisan
Barath Jagadisan
Objectives: Guidelines on functional constipation recommend digital rectal examination (DRE) when constipation is doubtful or with a suspicion of organic etiology. The guidelines do not clarify if DRE is mandatory to diagnose impaction. This study aims to determine the frequency of impaction detectable only on DRE among children satisfying Rome III criteria without requiring DRE and also the inter‐observer influences on impaction detection by DRE.Methods: Children between 6 months to 13 years of age, presenting with history suggestive of constipation were assessed. After excluding those with suspicion of organic etiology, those who needed DRE for diagnosis of constipation and those who do not satisfy Rome III criteria without DRE, the rest who satisfied Rome III criteria were assessed for impaction by palpable fecoliths or constipation‐associated fecal incontinence. Those without such impaction were randomized to 2 examiners for DRE to diagnose impaction, in the absence of contraindications.Results: Two hundred and thirty‐three children were assessed. One hundred and sixty‐nine satisfied Rome III without needing DRE. Forty‐eight (28.4%) had impaction detectable without DRE. Among the rest, 28 (30.1%) had impaction by DRE. There was no difference between the frequency of impaction detected by the 2 examiners. Clinical characteristics were similar (P > 0.05) between those with impaction detectable by DRE and those without.Conclusions: DRE does detect cases of impaction not discernible by other means. Such a finding may be comparable between examiners. These children may be identified by other clinical characteristics. The clinical significance of such a finding needs more understanding from the standpoint of therapeutic choices.

25 July 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EFEmer Fitzpatrick
Emer Fitzpatrick
CFCeline Filippi
Celine Filippi
BJBarath Jagadisan
Barath Jagadisan
DSDharshene Shivapatham
Dharshene Shivapatham
HAHanish Anand
Hanish Anand
ADAnil Dhawan
Anil Dhawan
Background: Pediatric acute liver failure (PALF) carries a high mortality without liver transplantation (LT) in children. Liver transplantation, though lifesaving, is limited by timely donor organ availability, the risks of major surgery and complications of life-long immunosuppression. Hepatocyte transplantation (HT) improves synthetic and detoxification functions in small animal models. The encapsulation of hepatocytes in alginate protects it from the recipient immune system while the intraperitoneal route of administration allows large volumes to be infused. The safety and possibly short-term efficacy of encapsulated hepatocytes has been observed in a named patient use. A novel type of microbeads (HMB002) has been developed, using a modified alginate and mesenchymal stromal cells (MSCs). Its safety and medium-term efficacy need to be studied in the context of clinical study while optimizing the hepatocyte function and viability using modifications of the alginate and MSCs co-encapsulation. Methods: A single centre, non-randomised, open-label, single-arm Simon’s two stage study will be conducted to evaluate the safety, biological activity and tolerability of transplantation of a single intraperitoneal dose of microbeads made from an optimum combination of a modified alginate, MSCs and hepatocytes in 17 patients less than 16 years of age with acute liver failure (Stage 1: 9 patients and Stage 2: 8 patient). Safety will be assessed by documenting moderate to severe (including life threatening and death) adverse events due to HMB002 in the first 52 weeks post-procedure. Tolerability will be assessed by observing the proportion of initiated infusions where >80% of infusion is received by the patient. Biological activity will be reflected in patient survival with native liver at 24 weeks post treatment. Discussion: HMB002, if safe and efficacious in acute liver failure, could be a bridge until the liver regenerates or a suitable organ becomes available. There are multiple advantages to using HT. HT, when delivered by the intraperitoneal route, is less invasive than LT. Hepatocytes from a single donor liver can be used to treat multiple patients. Cryopreserved cells provide an off-the-shelf emergency treatment in PALF. When encapsulated, alginate encapsulation of hepatocytes precludes the need for immunosuppression unlike in LT.